Darby I A, Coezy E D, Mizrahi J, Cantau B, Donnadieu M H, Nussberger J, Corvol P
INSERM U36, Paris, France.
J Hypertens Suppl. 1988 Dec;6(4):S446-8. doi: 10.1097/00004872-198812040-00140.
Specific binding sites for angiotensin II (Ang II) were identified in a human hepatoma cell line, HepG2. Binding of [125I]-Sar1 Ang II to these cells showed a high-affinity site with a Kd of 2.4 +/- 0.2 nmol/l. This specific binding was not changed during the cell cycle and showed no alteration after 24 h of treatment with Sar1-Ang II (10(-8) mol/l). Exposure of HepG2 cells to the Ang II agonist Sar1-Ang II caused a dose-dependent decrease in angiotensinogen production. The maximal inhibitory effect was at a dose of 10(-6) mol/l Sar1-Ang II which elicited 67% inhibition of angiotensinogen production after 24 h (control: 2.015 +/- 0.5 micrograms angiotensinogen/mg DNA; Sar1-Ang II 10(-6) mol/l: 0.68 +/- 0.03 micrograms angiotensinogen/mg DNA). Fifty per cent inhibition was obtained at a dose of 10(-9) mol/l Sar1-Ang II. Angiotensin II had a less marked effect, showing maximal inhibition of 40%. This study shows that the HepG2 cells possess specific Ang II binding sites and that Ang II analogues induce a dose-dependent inhibition of angiotensinogen production in cell culture.
在人肝癌细胞系HepG2中鉴定出血管紧张素II(Ang II)的特异性结合位点。[125I]-Sar1 Ang II与这些细胞的结合显示出一个高亲和力位点,解离常数(Kd)为2.4±0.2 nmol/l。这种特异性结合在细胞周期中没有变化,在用Sar1-Ang II(10^(-8) mol/l)处理24小时后也没有改变。将HepG2细胞暴露于Ang II激动剂Sar1-Ang II会导致血管紧张素原生成呈剂量依赖性减少。最大抑制作用出现在10^(-6) mol/l Sar1-Ang II的剂量下,24小时后引起血管紧张素原生成67%的抑制(对照:2.015±0.5微克血管紧张素原/毫克DNA;Sar1-Ang II 10^(-6) mol/l:0.68±0.03微克血管紧张素原/毫克DNA)。在10^(-9) mol/l Sar1-Ang II的剂量下可获得50%的抑制率。血管紧张素II的作用不太明显,最大抑制率为40%。这项研究表明,HepG2细胞具有特异性的Ang II结合位点,并且Ang II类似物在细胞培养中可诱导血管紧张素原生成的剂量依赖性抑制。